Trying to deliver in the future

Article Abstract:

Shire Pharmaceuticals is acquiring Pharmavene, a biotechnology concern, for 105 million pounds sterling. The deal involves 15 million pounds of an initial 55 million pounds to be paid in cash and the remainder in shares. Drug delivery is an expanding market and Pharmavene offers a range of drug delivery technologies. Pharmavene also brings 11 possible drugs to Shire Pharmaceuticals. An epilepsy drug has been registered in the US. The deal also involves risks for Shire.

Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, Mergers, acquisitions and divestments, Shire Pharmaceuticals Group PLC, Pharmavene Inc.

---

Sygen

Article Abstract:

Pig breeder Sygen International is enjoying buoyant growth and its shares are tipped as a good buy. Sygen provides farmers with disease-resistant pigs, and now wants to move into the higher-growth poultry and fish sectors.

Hogs, Hog and Pig Farming, Securities, Swine, Animal breeders, Sygen International

---

Similar abstracts:

• Abstracts: Making the scientists fulfil their promises. Mergers could save wilting sector. Mapping the genome busters. (biotechnology company shares_
• Abstracts: Picking the best of the promise keepers. Pooling resources to beat the market
• Abstracts: Waiting for the upturn. The Asian turmoil and those that survived it
• Abstracts: Tuning up the orchestra. The politics of the true and fair view. Members Handbook Statement 1.220: Guidance on Ethical Matters for Members in Business
• Abstracts: Moving with the times. Financing Asia's trade. Discounted debt

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.